Clinical trial · Observational

CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Contribution in Pathology Diagnosis and Molecular Biology

CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Pathology Diagnosis and Molecular Biology

NCT03386916CI-TRIAL-00030978stasfaunknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up. Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer. This study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected. This study is observational, retrospective, one center

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Image-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer	Procedure	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

label
Patient with a CT scan guide percutaneous biopsy of lytic bone
description
Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
interventionNames
1. Procedure: CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer

Primary outcomes (1)

measure
Rentability of biopsy of lytic bone lesion in anatomopathologic analysis
timeFrame
Analysis between january 2018-september 2018
description
Rentability of biopsy of lytic bone lesion = 100x (number of sample wich analysed by anatomopathologic /total number of biopsy of lytic bone lesion done)

Secondary outcomes (4)

measure
Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* CT scan guide percutaneous biopsy of lytic bone metastases
* register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
* Patient who have a clinical context of lung cancer with bone metastases

Exclusion Criteria:

* Person deprived of liberty by judicial order
* Opposition expressed by patient

References

Publications (5)

BACKGROUNDJelinek JS, Murphey MD, Welker JA, Henshaw RM, Kransdorf MJ, Shmookler BM, Malawer MM. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology. 2002 Jun;223(3):731-7. doi: 10.1148/radiol.2233011050. PMID 12034942
BACKGROUNDFraser-Hill MA, Renfrew DL. Percutaneous needle biopsy of musculoskeletal lesions. 1. Effective accuracy and diagnostic utility. AJR Am J Roentgenol. 1992 Apr;158(4):809-12. doi: 10.2214/ajr.158.4.1546597. PMID 1546597
BACKGROUNDLeffler SG, Chew FS. CT-guided percutaneous biopsy of sclerotic bone lesions: diagnostic yield and accuracy. AJR Am J Roentgenol. 1999 May;172(5):1389-92. doi: 10.2214/ajr.172.5.10227522. PMID 10227522
BACKGROUNDVieillard MH, Boutry N, Chastanet P, Duquesnoy B, Cotten A, Cortet B. Contribution of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. Joint Bone Spine. 2005 Jan;72(1):53-60. doi: 10.1016/j.jbspin.2004.03.008. PMID 15681249
BACKGROUNDVanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28. PMID 24513263